<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Moderately increased albuminuria (microalbuminuria) and cardiovascular disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Moderately increased albuminuria (microalbuminuria) and cardiovascular disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Moderately increased albuminuria (microalbuminuria) and cardiovascular disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George L Bakris, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 30, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION, TERMINOLOGY, AND DEFINITIONS</span><span class="headingEndMark"> — </span>The urine dipstick is a relatively insensitive marker for albuminuria, not becoming positive until albumin excretion exceeds 300 to 500 mg/day. Using a specific assay for albumin is a more sensitive technique. The normal rate of albumin excretion is less than 30 mg/day (20 mcg/min); persistent albumin excretion between 30 and 300 mg/day (20 to 200 mcg/min) is called moderately increased albuminuria (formerly called "microalbuminuria") [<a href="#rid1">1,2</a>]. Albumin excretion above 300 mg/day (200 mcg/min) is considered to represent overt or dipstick positive proteinuria (also called severely increased albuminuria [formerly called "macroalbuminuria"]). (See  <a class="medical medical_review" href="/z/d/html/16406.html" rel="external">"Definition and staging of chronic kidney disease in adults"</a>.)</p><p>The distinction between the terms "albuminuria" and "proteinuria" is discussed elsewhere in detail. (See  <a class="medical medical_review" href="/z/d/html/3101.html" rel="external">"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults", section on 'Definitions'</a>.)</p><p>Initial studies demonstrated that moderately increased albuminuria may be the earliest clinical manifestation of diabetic nephropathy in patients with type 1 diabetes, and first begins to appear five years after diagnosis. This is no longer thought to be the case, as albuminuria levels are quite variable early in the course of disease [<a href="#rid3">3-5</a>]. In addition, many individuals with diabetes progress to end-stage kidney disease without ever having significantly elevated albuminuria [<a href="#rid6">6,7</a>]. (See  <a class="medical medical_review" href="/z/d/html/119881.html" rel="external">"Diabetic kidney disease: Manifestations, evaluation, and diagnosis", section on 'Natural history'</a>.)</p><p>Moderately increased albuminuria is often present at diagnosis in patients with type 2 diabetes and may reflect underlying cardiovascular disease rather than diabetic kidney disease. </p><p>Yearly testing for albuminuria is recommended in patients with both type 1 diabetes (starting five years after disease onset) and type 2 diabetes (starting at disease onset). Assessment of albuminuria and estimated glomerular filtration rate are needed for kidney disease staging [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/3110.html" rel="external">"Moderately increased albuminuria (microalbuminuria) in type 1 diabetes mellitus"</a> and  <a class="medical medical_review" href="/z/d/html/3089.html" rel="external">"Moderately increased albuminuria (microalbuminuria) in type 2 diabetes mellitus"</a>.)</p><p>In addition to being associated with diabetic nephropathy, moderately increased albuminuria is associated with cardiovascular disease in both patients with and without diabetes. These studies will be reviewed here.</p><p class="headingAnchor" id="H2"><span class="h1">DETECTION</span><span class="headingEndMark"> — </span>Establishing the diagnosis of moderately increased albuminuria (formerly called "microalbuminuria") requires the demonstration of a <strong>persistent</strong> elevation in albumin excretion above 30 mg/day. <strong>Transient</strong> elevations in the excretion of albumin can be seen in the following settings [<a href="#rid9">9</a>] (see  <a class="medical medical_review" href="/z/d/html/3101.html" rel="external">"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Fever</p><p class="bulletIndent1"><span class="glyph">●</span>Infection</p><p class="bulletIndent1"><span class="glyph">●</span>Exercise</p><p class="bulletIndent1"><span class="glyph">●</span>Heart failure</p><p class="bulletIndent1"><span class="glyph">●</span>Nonspecific joint inflammation</p><p class="bulletIndent1"><span class="glyph">●</span>Poor glycemic control (hemoglobin A1c greater than 8 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Elevation in blood pressure (greater than 160/100 mmHg)</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperlipidemia (LDL cholesterol greater than 120 mg/dL)</p><p></p><p class="headingAnchor" id="H3"><span class="h2">Urine albumin concentration</span><span class="headingEndMark"> — </span>Although 24-hour urine collection is the gold standard for the detection of moderately increased albuminuria [<a href="#rid9">9,10</a>], it has been suggested that screening can be more simply achieved by a timed urine collection or an early morning specimen to minimize changes in urine volume that occur during the day [<a href="#rid9">9</a>]. moderately increased albuminuria is unlikely if the albumin excretion rate is below 20 mcg/min in a timed collection or the urine albumin concentration is less than 20 to 30 mg/L in a random specimen. Higher values (particularly those just above this range) may represent false positive results and should be confirmed by repeated measurements [<a href="#rid9">9</a>].</p><p>There are also a variety of semiquantitative dipsticks, such as Clinitek Microalbumin Dipsticks and Micral-Test II test strips, which can be used to test for moderately increased albuminuria if urine albumin excretion cannot be directly measured. The reported sensitivity and specificity of these tests range from 80 to 97 percent and 33 to 80 percent, respectively [<a href="#rid11">11</a>]. However, none of these approaches are recommended over formal quantitation [<a href="#rid12">12</a>].</p><p>The dipstick assessment, however, is the least sensitive and specific for determination of albuminuria [<a href="#rid12">12</a>]. One problem with measuring the urine albumin concentration or estimating it with a sensitive dipstick is that false negative and false positive results can occur since the urine albumin concentration is determined by the urine volume as well as the amount of albuminuria [<a href="#rid13">13</a>]. Thus, at a particular rate of albumin excretion, a substantial increase or decrease in urine volume will respectively lower and raise the urine albumin concentration. The confounding effect of the urine volume can be minimized by repeated measurements on early morning specimens [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Albumin-to-creatinine ratio</span><span class="headingEndMark"> — </span>The confounding effect of variations in urine volume on the urine albumin concentration can be avoided by calculation of the urine albumin-to-creatinine ratio in an untimed urine specimen. A value 30 to 300 mg/g of creatinine (or, using standard [SI] units, 3.4 to 34 mg/mmol of creatinine) suggests that albumin excretion is between 30 and 300 mg/day and therefore that moderately increased albuminuria is probably present [<a href="#rid14">14</a>]. Values above 300 mg/g (or 34 mg/mmol) are indicative of severely increased albuminuria (formerly called "macroalbuminuria"). This classification system requires that at least two of three specimens fall within the high or very high albuminuric range [<a href="#rid14">14</a>].</p><p>In one report, 24-hour urine collections and random, single-void urine specimens for albumin and creatinine were obtained in 14 normal subjects, 13 with type 1 diabetes, and 12 with type 2 diabetes [<a href="#rid15">15</a>]. A close correlation was noted between the two measurements and the within-patient variability was small. A random albumin-to-creatinine ratio above 30 mg/g had a sensitivity of 100 percent for the detection of moderately increased albuminuria. Similar findings have been noted by others [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H5"><span class="h3">Limitations</span><span class="headingEndMark"> — </span>There are three important caveats that must be considered to maximize the reliability of the urine albumin-to-creatinine ratio:</p><p class="bulletIndent1"><span class="glyph">●</span>Vigorous exercise can cause a transient increase in albumin excretion [<a href="#rid17">17</a>]. As a result, patients should refrain from vigorous exercise in the 24 hours prior to the test.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The optimal time to measure the urine albumin-to-creatinine ratio is uncertain. The best data come from reports that primarily evaluated patients without diabetes. In an initial study, the best correlation with a 24 hour urine collection occurred with samples obtained after the first morning void and before bedtime [<a href="#rid18">18</a>]. By contrast, a later and larger study found the best correlation with the first morning void although the difference with collections at other times was not significant [<a href="#rid19">19</a>]. Given the uncertainty, we suggest that first morning void specimens are preferred and, if this cannot be done, serial specimens should always be obtained at the same time of day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The accuracy of the urine albumin-to-creatinine ratio will be diminished if creatinine excretion is substantially different from the expected value; this is particularly important in patients with borderline values. Albumin excretion will be underestimated in a muscular man with a high rate of creatinine excretion and overestimated in a cachectic patient in whom muscle mass and creatinine excretion are markedly reduced. The ratio also varies with race/ethnicity in the United States, as creatinine excretion is significantly higher among non-Hispanic Black Americans and Hispanic Americans than among non-Hispanic White Americans [<a href="#rid20">20</a>].</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Recommendations</span><span class="headingEndMark"> — </span>Measurement of the urine albumin-to-creatinine ratio in an untimed urinary sample is the preferred screening strategy for moderately increased albuminuria [<a href="#rid9">9,14,21</a>]. This test has the following advantages: it does not require early morning or timed collections, it gives a quantitative result that correlates with the 24-hour urine values over a wide range of protein excretion, it is simple to perform and inexpensive, and repeat values can be easily obtained to ascertain that moderately increased albuminuria, if present, is persistent.</p><p class="headingAnchor" id="H7"><span class="h1">CORRELATION OF MODERATELY INCREASED ALBUMINURIA (MICROALBUMINURIA) WITH CARDIOVASCULAR DISEASE</span><span class="headingEndMark"> — </span>Post hoc analyses in different patient populations have suggested that, in addition to its relation to kidney disease, moderate increases in albuminuria (formerly called "microalbuminuria") over time are an important risk factor for cardiovascular disease and early cardiovascular mortality in patients with and without diabetes and/or hypertension [<a href="#rid22">22-43</a>]. Among patients with chronic kidney disease, observational studies have suggested a graded increase in coronary risk with the presence of overt proteinuria as measured with a urinary dipstick. (See  <a class="medical medical_review" href="/z/d/html/7190.html" rel="external">"Chronic kidney disease and coronary heart disease"</a>.)</p><p>The following observations represent data from different groups of patients, ranging from those with cardiovascular disease to population-based cohorts.</p><p class="headingAnchor" id="H8"><span class="h2">Clinical trials</span><span class="headingEndMark"> — </span>Among over 9000 participants at high risk for a cardiovascular event in the HOPE (Heart Outcomes Prevention Evaluation) trial, the presence of moderately increased albuminuria was associated with an increased relative risk of the primary aggregate end point (myocardial infarction [MI], stroke, or cardiovascular death) in those with and without diabetes (1.97 and 1.61, respectively) [<a href="#rid24">24</a>]. The risk of an adverse cardiovascular event increased progressively with increasing absolute levels of moderately increased albuminuria. (See  <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a>.)</p><p>An increase in risk was also noted a post hoc analysis from the LIFE trial of patients with hypertension and electrocardiographic evidence of left ventricular hypertrophy, the urine albumin-to-creatinine ratio was measured in 7143 nondiabetic subjects (median value 10.2 mg/g creatinine [1.16 mg/mmol]) and 1063 subjects with diabetes (median value 26.9 mg/g creatinine [3.05 mg/mmol]) [<a href="#rid25">25</a>]. For every 10-fold increase in the albumin-to-creatinine ratio, the risk of the composite end point of cardiovascular death, MI, or stroke increased by 57 percent and the risk of cardiovascular death by 98 percent among nondiabetics. The respective increases in risk for diabetics were 39 and 47 percent. A subsequent analysis of this trial showed that the risk of the composite end point of cardiovascular death, MI, or stroke was reduced among participants who had a substantial reduction in moderately increased albuminuria at the one-year follow-up [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Population-based studies</span><span class="headingEndMark"> — </span>A number of population-based studies have identified moderately increased albuminuria as a significant predictor of cardiovascular risk [<a href="#rid22">22,23,26,27,45</a>]. In an analysis from the Prevention of Renal and Vascular End Stage Disease (PREVEND) study, urinary albumin excretion was measured in a general population sample of 40,548 participants who were followed for a median of 2.6 years [<a href="#rid26">26</a>]. There were 518 deaths (1.3 percent) of which 178 were cardiovascular deaths (0.4 percent). When adjusted for age and sex, there was a graded increase in the relative risk of cardiovascular mortality of 1.35 for each doubling of urinary albumin excretion. A potential limitation of this study is that the urine albumin concentration, rather than the albumin-to-creatinine ratio was used.</p><p>The mortality risk in postmenopausal females was evaluated in a population-based cohort study of 12,239 postmenopausal females [<a href="#rid27">27</a>]. Cardiovascular mortality was increased in those in the highest quintile of urinary albumin excretion (&gt;21 mg/g creatinine [&gt;2.41 mg/mmol]) compared with females without detectable albuminuria (13.2 versus 2.6 per 1000 years, age-adjusted rate ratio 4.4) [<a href="#rid27">27</a>]. This relationship was independent of diabetes and hypertension.</p><p class="headingAnchor" id="H10"><span class="h2">High-normal albuminuria</span><span class="headingEndMark"> — </span>Higher levels of albumin excretion within the normal range, well under the above definitions for moderately increased albuminuria (≥30 mg/day [20 mcg/min] or urine albumin-to-creatinine ratio ≥30 mg/g), are associated with an increase in cardiovascular risk that is additive to conventional risk factors [<a href="#rid28">28,29,46-49</a>]. The following observations illustrated the range of findings:</p><p class="bulletIndent1"><span class="glyph">●</span>In the Third Copenhagen Heart Study, 2726 patients underwent a urine collection for measurement of albumin and were followed for the development of coronary heart disease or death [<a href="#rid28">28</a>]. Patients in the top quartile of urinary albumin excretion (&gt;4.8 mcg/min [6.9 mg/day]) had an adjusted relative risk of death of 1.9 and of coronary heart disease of 2.0. Among the hypertensive participants, the cumulative incidence of heart disease (11 versus 5 percent) and mortality (28 versus 13 percent) were significantly increased with urinary albumin excretion ≥5 mcg/min (&gt;7.2 mg/day) compared with values below 5 mcg/min. The adjusted relative risk for coronary heart disease and mortality were 2.0 and 1.9, after adjustment for other risk factors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar findings with very low levels of albuminuria were noted in a review from the Framingham Heart Study of 1568 nonhypertensive, nondiabetic individuals (mean age 55) [<a href="#rid46">46</a>]. At a median follow-up of six years, 54 participants developed a first cardiovascular event and 49 died. Participants with a urine albumin-to-creatinine ratio above the median (≥3.9 and ≥7.5 mg/g in males and females, respectively) had a significant increase in the risk of a first cardiovascular event (5.1 versus 1.8 percent, adjusted hazard ratio [HR] 2.92, 95% CI 1.57-5.44) and an almost significant increase in mortality (4.2 versus 2.0 percent, adjusted HR 1.75, 95% CI 0.95-3.22). The increase in risk remained significant in participants with a low or intermediate pretest probability of cardiovascular disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another report from the Framingham Heart Study demonstrated the association of high-normal albumin excretion with the risks of hypertension and blood pressure progression in 1499 nonhypertensive, nondiabetic individuals [<a href="#rid29">29</a>]. At a mean follow-up of 2.9 years, 15 percent developed hypertension and 33 percent progressed to a higher blood pressure category. The odds ratio in the highest quartile of urine albumin-to-creatinine ratio (&gt;6.7 and 15.2 mg/g in males and females, respectively) compared with the lowest quartile was 1.93 and 1.45 for developing hypertension and progressive hypertension, respectively.</p><p></p><p>In a multivariable analysis adjusting for known risk factors, the adjusted odds ratio for developing hypertension was 1.20 for every 1 standard deviation in urine albumin-to-creatinine ratio. Compared with those in the lowest urine albumin-to-creatinine ratio quartile, individuals in the highest quartile (males 6.6 mg/g, females 15.4 mg/g) had an adjusted odds ratio of 1.93 for developing hypertension and 1.45 for blood pressure progression.</p><p class="headingAnchor" id="H11"><span class="h2">ST and T wave changes</span><span class="headingEndMark"> — </span>The presence of moderately increased albuminuria also enhances the predictive value of ST and T wave changes for cardiovascular disease. This was illustrated in another analysis from the population-based PREVEND study [<a href="#rid30">30</a>]. Among 7330 subjects, 1244 had ST-T changes; 885 had moderately increased albuminuria (mean albumin excretion 53 mg/day); and 223 had both. At a median follow-up of six years, the patients with both ST-T changes and moderately increased albuminuria compared with those with ST-T changes alone had marked increases in the incidence of all-cause mortality (7.2 versus 1.1 percent) and cardiovascular mortality (2.7 versus 0.5 percent). Moderately increased albuminuria had a greater impact on the risk of all-cause mortality than hypertension, hypercholesterolemia, cigarette smoking, obesity, or diabetes mellitus.</p><p class="headingAnchor" id="H12"><span class="h2">Possible mechanisms</span><span class="headingEndMark"> — </span>How moderately increased albuminuria is associated with cardiovascular disease is not well understood. Moderately increased albuminuria in patients without diabetes appears to be a signal from the kidney that the vasculature, particularly the endothelium, is not functioning normally. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Vasodilation in response to certain stimuli is relatively reduced in older "normal individuals" with moderately increased albuminuria compared with those with lower levels of albumin excretion [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among patients without diabetes with primary hypertension (formerly called "essential" hypertension), those with moderately increased albuminuria had higher plasma levels of von Willebrand factor (vWf) antigen than patients with normal albumin excretion [<a href="#rid51">51</a>]; furthermore, individual vWf and albumin excretion values were significantly correlated. vWf has been associated with occlusive thrombosis; thus, the increased plasma vWf levels might directly contribute to the enhanced cardiovascular risk.</p><p></p><p>Endothelial dysfunction is also present in patients with diabetes [<a href="#rid32">32</a>], and the degree of coronary endothelial dysfunction appears to be greater in patients with moderately increased albuminuria [<a href="#rid52">52</a>]. One important factor may be hyperglycemia-induced alterations in extracellular matrix, such as decreased density of heparan sulfate proteoglycans. This abnormality can lead to increased microvascular permeability, resulting in moderately increased albuminuria at the glomerulus and perhaps increased lipoprotein deposition in peripheral vessels.</p><p>The apparent association between moderately increased albuminuria and cardiovascular disease is in part related to an adverse risk factor profile in patients with and without diabetes [<a href="#rid36">36,53-56</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In the Cardiovascular Health Study of almost 1100 older adults who did not have diabetes mellitus or hypertension, moderately increased albuminuria was associated with increasing age, increasing systolic blood pressure, and inflammatory markers (such as C-reactive protein levels) [<a href="#rid53">53</a>]. The importance of blood pressure was also noted in report of almost 8800 individuals without diabetes mellitus or hypertension in the Third National Health and Nutrition Examination Survey (NHANES) [<a href="#rid54">54</a>]. Compared with optimal blood pressure (&lt;120/&lt;80 mmHg), high-normal blood pressure (130 to 139/85 to 89 mmHg) was associated with a significant increase in the risk of moderately increased albuminuria (odds ratio 1.3 per 10 mmHg increase in systolic or diastolic pressure). (See  <a class="medical medical_review" href="/z/d/html/1484.html" rel="external">"C-reactive protein in cardiovascular disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a cross-sectional analysis of 1160 patients with type 1 diabetes in the Diabetes Control and Complications Trial, as progressive increases in albuminuria were associated with elevations in proatherogenic intermediate-density lipoprotein and small dense LDL particles [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a cross-sectional study of patients with type 2 diabetes with preserved kidney function (median GFR 87 mL/min per 1.73 m<sup>2</sup>), the urine albumin-to-creatinine ratio (ACR) was positively correlated with coronary and carotid artery calcification as defined by scores derived from computed tomography [<a href="#rid56">56</a>].</p><p></p><p class="headingAnchor" id="H13"><span class="h1">CORRELATION OF CARDIOVASCULAR DISEASE WITH MODERATELY INCREASED ALBUMINURIA (MICROALBUMINURIA)</span><span class="headingEndMark"> — </span>The association between moderately increased albuminuria (formerly called "microalbuminuria") and cardiovascular disease also extends to the development of moderately increased albuminuria and/or progression to severely increased albuminuria among patients at high cardiovascular risk. This was shown in a retrospective analysis of the HOPE trial, in which 1859 of 7674 patients either developed new moderately increased albuminuria (1542 patients) or new clinical albuminuria (317 participants) [<a href="#rid57">57</a>]. Enrolled patients were at high risk for adverse cardiovascular outcome, which was defined as either:</p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of vascular disease, including coronary heart disease (81 percent, with a prior history of myocardial infarction [MI] in 53 percent), stroke, or peripheral vascular disease</p><p></p><p class="bulletIndent1"><strong>or</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes and at least one other coronary risk factor (serum total cholesterol above 200 mg/dL [5.2 mmol/L], low serum HDL cholesterol, hypertension [present in 56 percent], moderately increased albuminuria, or current smoking)</p><p></p><p>The administration of <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">ramipril</a>, compared with placebo, decreased the risk for progressive kidney function loss (odds ratio 0.87). It is not clear if the benefit was derived from angiotensin-converting enzyme (ACE) inhibition or from blood pressure lowering. (See  <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a>.)</p><p>In a subsequent meta-analysis of 41 treatment trials and 29,979 participants, a reduction in albumin excretion of 30 percent or more was associated with a 27 percent relative risk reduction in the incidence of doubling of serum creatinine or progression to kidney failure [<a href="#rid58">58</a>]. This finding has led the American Diabetes Association to suggest targeting a reduction in albuminuria of at least 30 percent [<a href="#rid8">8</a>]. </p><p class="headingAnchor" id="H14"><span class="h1">SCREENING</span><span class="headingEndMark"> — </span>We test for moderately increased albuminuria (formerly called "microalbuminuria") among patients with diabetes to screen for cardiovascular risk and to look for changes over time that would indicate the presence of nephropathy. Moderately increased albuminuria is often present at diagnosis in patients with type 2 diabetes. (See  <a class="medical medical_review" href="/z/d/html/3089.html" rel="external">"Moderately increased albuminuria (microalbuminuria) in type 2 diabetes mellitus"</a>.)</p><p>The value of measuring albumin excretion in patients with primary hypertension without diabetes is advocated by some to assess cardiovascular risk; however, it may not be cost effective in this context, and it does not have value as a screening tool for nephropathy in patients without diabetes with hypertension [<a href="#rid17">17,18</a>].</p><p>As described above, there is evidence of an increase in mortality risk with moderately increased albuminuria that is independent of diabetes [<a href="#rid26">26,27,43</a>]. Nevertheless, we do <strong>not</strong> screen for moderately increased albuminuria in the general population of patients without diabetes, since the value of screening in these patients is unclear; the ability of any therapies to provide benefit in this setting is unknown, and it is not cost effective [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H15"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>There is increasing evidence that even stage 3 chronic kidney disease (estimated glomerular filtration rate ≤60 mL/min) is associated with an increased risk of cardiovascular disease. As a result, chronic kidney disease is considered by many to be a coronary equivalent that should be managed according to secondary prevention goals. (See  <a class="medical medical_review" href="/z/d/html/7190.html" rel="external">"Chronic kidney disease and coronary heart disease"</a> and  <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a>.)</p><p>The KDIGO guidelines suggest that moderately increased albuminuria (formerly called "microalbuminuria") alone that persists for more than three months falls within the definition of chronic kidney disease (see  <a class="medical medical_review" href="/z/d/html/16406.html" rel="external">"Definition and staging of chronic kidney disease in adults"</a>). Some authorities disagree, suggesting that isolated moderately increased albuminuria (without a reduction in glomerular filtration rate) represents generalized endothelial dysfunction and inflammation. Regardless, blockers of the renin-angiotensin system (eg, angiotensin-converting enzyme [ACE] inhibitors) are not appropriate in patients with normal blood pressure and only moderately increased albuminuria.</p><p>Even if moderately increased albuminuria does not, by itself, signify chronic kidney disease, it is clearly associated with an increase in cardiovascular risk as described above. Both moderately increased albuminuria and severely increased albuminuria are treated in patients with diabetes to slow the progression of diabetic nephropathy. Post hoc analyses of trials that enrolled patients with stage 3b and 4 chronic kidney disease showed that reducing albuminuria by 30 percent or more correlates with slowed progression of nephropathy. However, the ACCOMPLISH and ROADMAP trials failed to show a cardiovascular benefit from reduction in albuminuria. (See  <a class="medical medical_review" href="/z/d/html/3110.html" rel="external">"Moderately increased albuminuria (microalbuminuria) in type 1 diabetes mellitus"</a> and  <a class="medical medical_review" href="/z/d/html/3052.html" rel="external">"Treatment of diabetic kidney disease"</a> and  <a class="medical medical_review" href="/z/d/html/3829.html" rel="external">"Treatment of hypertension in patients with diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Antihypertensive drugs</span><span class="headingEndMark"> — </span>Several studies have examined the effects of antihypertensive therapy on moderately increased albuminuria and clinical cardiovascular outcomes. Angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are equally effective in reducing albuminuria [<a href="#rid60">60</a>]. However, ACE inhibitors and ARBs should not be used in combination. (See  <a class="medical medical_review" href="/z/d/html/3816.html" rel="external">"Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers", section on 'Combination of ACE inhibitors and ARBs'</a>.)</p><p>In the PREVEND IT trial, 846 normotensive patients with "normal" serum cholesterol (mean total cholesterol 223 mg/dL [5.8 mmol/L]), mean LDL cholesterol 154 [4.0 mmol/L], and moderately increased albuminuria [15 to 300 mg/24 hours] were randomly assigned to <a class="drug drug_general" data-topicid="8479" href="/z/d/drug information/8479.html" rel="external">fosinopril</a> or placebo and to <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">pravastatin</a> or placebo [<a href="#rid61">61</a>]. This was largely a primary prevention study since only 3.4 percent had a history of a prior cardiovascular event.</p><p>At follow-up of almost four years, <a class="drug drug_general" data-topicid="8479" href="/z/d/drug information/8479.html" rel="external">fosinopril</a> significantly lowered urinary protein excretion and was associated with a nonsignificant trend toward a lower rate of the primary end point of cardiovascular mortality or hospitalization for cardiovascular morbidity (hazard ratio [HR] 0.60, 95% CI 0.33-1.10). Similar findings were noted in two post hoc subset analyses of the LIFE trial; reductions in baseline albuminuria, which were more pronounced with <a class="drug drug_general" data-topicid="9574" href="/z/d/drug information/9574.html" rel="external">losartan</a> than <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a>, were associated with enhanced cardiovascular benefits [<a href="#rid44">44,62</a>].</p><p>Reduced albumin excretion with ACE inhibitors is well described in patients without diabetes, while the possible cardiovascular benefit in PREVEND IT may have resulted from a significantly lower blood pressure (129/76 versus 132/78 mmHg for placebo), rather than a specific effect of angiotensin inhibition. (See  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a>.)</p><p>The IMPROVE trial was performed in an attempt to determine if combining an ACE inhibitor with an ARB reduced albuminuria more than an ACE inhibitor alone [<a href="#rid63">63,64</a>], although subsequent studies have found that combination therapy is potentially harmful and should not be used. IMPROVE randomly assigned 405 hypertensive patients with moderately increased albuminuria and increased cardiovascular risk to <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">ramipril</a> alone or ramipril plus <a class="drug drug_general" data-topicid="8640" href="/z/d/drug information/8640.html" rel="external">irbesartan</a>. The primary end point was the reduction in albumin excretion rate by week 20; cardiovascular outcomes were not assessed in this trial.</p><p>The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Combined therapy with <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">ramipril</a> and <a class="drug drug_general" data-topicid="8640" href="/z/d/drug information/8640.html" rel="external">irbesartan</a> was no more effective than ramipril alone in reducing albumin excretion in all patients with albuminuria.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subgroup analyses showed that combined therapy was more effective than <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">ramipril</a> alone in reducing albumin excretion rate in patients with overt nephropathy (defined as albuminuria &gt;200 mcg/min). The small number of patients and the large 95% CIs in both groups suggest that these data be interpreted with caution.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A greater reduction in both systolic and diastolic blood pressure was achieved in patients who received the combination of <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">ramipril</a> and <a class="drug drug_general" data-topicid="8640" href="/z/d/drug information/8640.html" rel="external">irbesartan</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The incidence of adverse effects was similar in both treatment groups.</p><p></p><p class="headingAnchor" id="H17"><span class="h2">Statin therapy</span><span class="headingEndMark"> — </span>In the <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">pravastatin</a> arm of the PREVEND IT trial, pravastatin significantly lowered both total cholesterol (223 to 185 mg/dL [5.8 versus 4.8 mmol/L]) and LDL cholesterol (158 to 119 mg/dL [4.1 versus 3.1 mmol/L]), while there was no change in the placebo group [<a href="#rid61">61</a>]. Pravastatin therapy did not reduce albumin excretion and was associated with a nonsignificant 13 percent reduction in the primary cardiovascular end point (5.0 versus 5.7 percent, HR 0.87, 95% CI 0.49-1.57) [<a href="#rid61">61</a>]. However, this study was underpowered for the cardiovascular outcome, and other primary prevention trials in patients with similar baseline lipid levels have shown a significant cardiovascular benefit from statin therapy.</p><p class="headingAnchor" id="H18"><span class="h2">Recommendations</span><span class="headingEndMark"> — </span>In the absence of clear data, the following represents our usual approach in patients <strong>without</strong> diabetes who are noted to have moderately increased albuminuria (see <a class="local">'Screening'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>Testing for moderately increased albuminuria should be repeated once or twice to make certain that it is a persistent abnormality. Possible inflammatory causes should be sought, such as periodontal disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among patients with persistent moderately increased albuminuria who are hypertensive, we would use an ACE inhibitor or ARB because of the greater ability to reduce albuminuria, but there are no data demonstrating an outcome benefit in this group, and, hence, blood pressure control is the key approach. (See  <a class="medical medical_review" href="/z/d/html/3110.html" rel="external">"Moderately increased albuminuria (microalbuminuria) in type 1 diabetes mellitus"</a> and  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Goal blood pressure depends upon the level of cardiovascular risk and tolerability of the antihypertensive regimen. (See  <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We recommend <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> therapy and suggest consideration of a statin in patients who also have other risk factors for cardiovascular disease. The goal LDL cholesterol concentration is well below 100 mg/dL (2.6 mmol/L). (See  <a class="medical medical_review" href="/z/d/html/1546.html" rel="external">"Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Albumin excretion should be monitored at regular intervals. Issues related to blood pressure and LDL cholesterol goals in patients with atherosclerotic cardiovascular disease are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"</a> and  <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a>.)</p><p></p><p>The management of patients with diabetes who have moderately increased albuminuria is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3110.html" rel="external">"Moderately increased albuminuria (microalbuminuria) in type 1 diabetes mellitus"</a>.)  </p><p class="headingAnchor" id="H220350"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Moderately increased albuminuria (formerly called "microalbuminuria") is defined as persistent albumin excretion between 30 and 300 mg/day (20 to 200 mcg/min). Moderately increased albuminuria (≥30 mg/day [20 mcg/min] or urine albumin-to-creatinine ratio ≥30 mg/g) is a marker associated with increased risk of cardiovascular disease that is additive to conventional risk factors in all patients regardless of diabetes status. (See <a class="local">'Introduction, terminology, and definitions'</a> above and <a class="local">'Correlation of moderately increased albuminuria (microalbuminuria) with cardiovascular disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Measurement of the urine albumin-to-creatinine ratio in an untimed urinary sample is the preferred screening strategy for moderately increased albuminuria. In order to maximize the reliability of the urine albumin-to-creatinine ratio, patients should refrain from vigorous exercise in the 24 hours prior to the test since vigorous exercise can cause a transient increase in albumin excretion. In addition, the accuracy of the albumin-to-creatinine ratio will be diminished if creatinine excretion is substantially different from the expected value, such as in a muscular or cachectic individual. (See <a class="local">'Detection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The mechanism by which moderately increased albuminuria is associated with cardiovascular disease is not well understood. However, moderately increased albuminuria appears to be a signal that the vasculature, particularly the endothelium, is not functioning normally. Among patients with diabetes, the degree of coronary endothelial dysfunction appears to be greater in patients with moderately increased albuminuria and may be related to hyperglycemia-induced alterations in extracellular matrix, such as decreased density of heparan sulfate proteoglycans. This abnormality can lead to increased microvascular permeability, resulting in moderately increased albuminuria at the glomerulus and perhaps increased lipoprotein deposition in peripheral vessels. (See <a class="local">'Possible mechanisms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We test for moderately increased albuminuria among patients with diabetes to screen for cardiovascular risk and to look for changes over time that would indicate the presence of nephropathy. We also screen for moderately increased albuminuria among patients without diabetes at increased risk for chronic kidney disease and cardiovascular disease, such as those with hypertension and the metabolic syndrome. We do <strong>not</strong> screen for moderately increased albuminuria in the general population of patients without diabetes without any such risk factors, since the value of screening in these patients is unclear; the ability of any therapies to provide benefit in this setting is unknown, and it is not cost effective. (See <a class="local">'Screening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The KDIGO guidelines suggest that moderately increased albuminuria alone that persists for more than three months falls within the definition of chronic kidney disease. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It is not certain that treatment specifically aimed at lowering albumin excretion in nondiabetics with moderately increased albuminuria is beneficial. In the absence of clear data, the following represents our usual approach in patients <strong>without diabetes</strong> who have moderately increased albuminuria. (See <a class="local">'Screening'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Testing for moderately increased albuminuria should be repeated at least twice to make certain that it is a persistent abnormality. Possible inflammatory causes should be sought, such as periodontal disease. Albumin excretion should be monitored at regular intervals.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among patients with persistent moderately increased albuminuria who are hypertensive, an angiotensin converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) lowers albuminuria more than other drugs but has not been shown to reduce cardiovascular events more than other antihypertensive agents in this group. (See  <a class="medical medical_review" href="/z/d/html/3110.html" rel="external">"Moderately increased albuminuria (microalbuminuria) in type 1 diabetes mellitus"</a> and  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Goal blood pressure depends upon cardiovascular risk and tolerability of therapy. (See  <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Issues related to blood pressure and LDL cholesterol goals in patients with atherosclerotic cardiovascular disease are discussed in detail separately. (See <a class="local">'Recommendations'</a> above and  <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"</a> and  <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We recommend <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> therapy and suggest consideration of a statin in patients who also have other risk factors for cardiovascular disease. The goal LDL cholesterol concentration is well below 100 mg/dL (2.6 mmol/L). (See  <a class="medical medical_review" href="/z/d/html/1546.html" rel="external">"Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Chapter 1: Definition and classification of CKD. Kidney Int Suppl (2011) 2013; 3:19.</a></li><li><a class="nounderline abstract_t">Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 2013; 158:825.</a></li><li><a class="nounderline abstract_t">Steinke JM, Sinaiko AR, Kramer MS, et al. The early natural history of nephropathy in Type 1 Diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes 2005; 54:2164.</a></li><li><a class="nounderline abstract_t">Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009; 361:40.</a></li><li><a class="nounderline abstract_t">Glassock RJ. Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 2010; 31:462.</a></li><li><a class="nounderline abstract_t">MacIsaac RJ, Ekinci EI. Progression of Diabetic Kidney Disease in the Absence of Albuminuria. Diabetes Care 2019; 42:1842.</a></li><li><a class="nounderline abstract_t">Vistisen D, Andersen GS, Hulman A, et al. Progressive Decline in Estimated Glomerular Filtration Rate in Patients With Diabetes After Moderate Loss in Kidney Function-Even Without Albuminuria. Diabetes Care 2019; 42:1886.</a></li><li><a class="nounderline abstract_t">American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022; 45:S175.</a></li><li><a class="nounderline abstract_t">Mogensen CE, Vestbo E, Poulsen PL, et al. Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Diabetes Care 1995; 18:572.</a></li><li><a class="nounderline abstract_t">Consensus development conference on the diagnosis and management of nephropathy in patients with diabetes mellitus. American Diabetes Association and the National Kidney Foundation. Diabetes Care 1994; 17:1357.</a></li><li><a class="nounderline abstract_t">Sacks DB, Arnold M, Bakris GL, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2011; 57:e1.</a></li><li><a class="nounderline abstract_t">Sacks DB, Arnold M, Bakris GL, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 2011; 34:e61.</a></li><li><a class="nounderline abstract_t">Schwab SJ, Dunn FL, Feinglos MN. Screening for microalbuminuria. A comparison of single sample methods of collection and techniques of albumin analysis. Diabetes Care 1992; 15:1581.</a></li><li><a class="nounderline abstract_t">KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007; 49:S12.</a></li><li><a class="nounderline abstract_t">Nathan DM, Rosenbaum C, Protasowicki VD. Single-void urine samples can be used to estimate quantitative microalbuminuria. Diabetes Care 1987; 10:414.</a></li><li><a class="nounderline abstract_t">Zelmanovitz T, Gross JL, Oliveira JR, et al. The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes Care 1997; 20:516.</a></li><li><a class="nounderline abstract_t">Jefferson IG, Greene SA, Smith MA, et al. Urine albumin to creatinine ratio-response to exercise in diabetes. Arch Dis Child 1985; 60:305.</a></li><li><a class="nounderline abstract_t">Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 1983; 309:1543.</a></li><li><a class="nounderline abstract_t">Witte EC, Lambers Heerspink HJ, de Zeeuw D, et al. First morning voids are more reliable than spot urine samples to assess microalbuminuria. J Am Soc Nephrol 2009; 20:436.</a></li><li><a class="nounderline abstract_t">Mattix HJ, Hsu CY, Shaykevich S, Curhan G. Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race. J Am Soc Nephrol 2002; 13:1034.</a></li><li><a class="nounderline abstract_t">Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 2003; 42:617.</a></li><li><a class="nounderline abstract_t">Fangel MV, Nielsen PB, Kristensen JK, et al. Albuminuria and Risk of Cardiovascular Events and Mortality in a General Population of Patients with Type 2 Diabetes Without Cardiovascular Disease: A Danish Cohort Study. Am J Med 2020; 133:e269.</a></li><li><a class="nounderline abstract_t">Patel RB, Colangelo LA, Reis JP, et al. Association of Longitudinal Trajectory of Albuminuria in Young Adulthood With Myocardial Structure and Function in Later Life: Coronary Artery Risk Development in Young Adults (CARDIA) Study. JAMA Cardiol 2020; 5:184.</a></li><li><a class="nounderline abstract_t">Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286:421.</a></li><li><a class="nounderline abstract_t">Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139:901.</a></li><li><a class="nounderline abstract_t">Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106:1777.</a></li><li><a class="nounderline abstract_t">Roest M, Banga JD, Janssen WM, et al. Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. Circulation 2001; 103:3057.</a></li><li><a class="nounderline abstract_t">Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004; 110:32.</a></li><li><a class="nounderline abstract_t">Wang TJ, Evans JC, Meigs JB, et al. Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation 2005; 111:1370.</a></li><li><a class="nounderline abstract_t">Diercks GF, Hillege HL, van Boven AJ, et al. Microalbuminuria modifies the mortality risk associated with electrocardiographic ST-T segment changes. J Am Coll Cardiol 2002; 40:1401.</a></li><li><a class="nounderline abstract_t">Mattock MB, Morrish NJ, Viberti G, et al. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 1992; 41:736.</a></li><li><a class="nounderline abstract_t">Stehouwer CD, Nauta JJ, Zeldenrust GC, et al. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992; 340:319.</a></li><li><a class="nounderline abstract_t">UK Prospective Diabetes Study (UKPDS). X. Urinary albumin excretion over 3 years in diet-treated type 2, (non-insulin-dependent) diabetic patients, and association with hypertension, hyperglycaemia and hypertriglyceridaemia. Diabetologia 1993; 36:1021.</a></li><li><a class="nounderline abstract_t">Feldt-Rasmussen B, Mathiesen ER, Deckert T. Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet 1986; 2:1300.</a></li><li><a class="nounderline abstract_t">Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000; 160:1093.</a></li><li><a class="nounderline abstract_t">Bianchi S, Bigazzi R, Campese VM. Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications. Am J Kidney Dis 1999; 34:973.</a></li><li><a class="nounderline abstract_t">Calviño J, Calvo C, Romero R, et al. Atherosclerosis profile and microalbuminuria in essential hypertension. Am J Kidney Dis 1999; 34:996.</a></li><li><a class="nounderline abstract_t">Wachtell K, Olsen MH, Dahlöf B, et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertens 2002; 20:405.</a></li><li><a class="nounderline abstract_t">Hoehner CM, Greenlund KJ, Rith-Najarian S, et al. Association of the insulin resistance syndrome and microalbuminuria among nondiabetic native Americans. The Inter-Tribal Heart Project. J Am Soc Nephrol 2002; 13:1626.</a></li><li><a class="nounderline abstract_t">De Leeuw PW, Thijs L, Birkenhäger WH, et al. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. J Am Soc Nephrol 2002; 13:2213.</a></li><li><a class="nounderline abstract_t">Muntner P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13:745.</a></li><li><a class="nounderline abstract_t">Romundstad S, Holmen J, Kvenild K, et al. Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Trøndelag Health Study (HUNT), Norway. Am J Kidney Dis 2003; 42:466.</a></li><li><a class="nounderline abstract_t">Kuusisto J, Mykkänen L, Pyörälä K, Laakso M. Hyperinsulinemic microalbuminuria. A new risk indicator for coronary heart disease. Circulation 1995; 91:831.</a></li><li><a class="nounderline abstract_t">Ibsen H, Olsen MH, Wachtell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45:198.</a></li><li><a class="nounderline abstract_t">McCullough PA, Jurkovitz CT, Pergola PE, et al. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med 2007; 167:1122.</a></li><li><a class="nounderline abstract_t">Arnlöv J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005; 112:969.</a></li><li><a class="nounderline abstract_t">Kistorp C, Raymond I, Pedersen F, et al. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005; 293:1609.</a></li><li><a class="nounderline abstract_t">Klausen KP, Scharling H, Jensen G, Jensen JS. New definition of microalbuminuria in hypertensive subjects: association with incident coronary heart disease and death. Hypertension 2005; 46:33.</a></li><li><a class="nounderline abstract_t">McQueen MJ, Gerstein HC, Pogue J, et al. Reevaluation by high-performance liquid chromatography: clinical significance of microalbuminuria in individuals at high risk of cardiovascular disease in the Heart Outcomes Prevention Evaluation (HOPE) Study. Am J Kidney Dis 2006; 48:889.</a></li><li><a class="nounderline abstract_t">Clausen P, Jensen JS, Jensen G, et al. Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation 2001; 103:1869.</a></li><li><a class="nounderline abstract_t">Pedrinelli R, Giampietro O, Carmassi F, et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994; 344:14.</a></li><li><a class="nounderline abstract_t">Cosson E, Pham I, Valensi P, et al. Impaired coronary endothelium-dependent vasodilation is associated with microalbuminuria in patients with type 2 diabetes and angiographically normal coronary arteries. Diabetes Care 2006; 29:107.</a></li><li><a class="nounderline abstract_t">Barzilay JI, Peterson D, Cushman M, et al. The relationship of cardiovascular risk factors to microalbuminuria in older adults with or without diabetes mellitus or hypertension: the cardiovascular health study. Am J Kidney Dis 2004; 44:25.</a></li><li><a class="nounderline abstract_t">Knight EL, Kramer HM, Curhan GC. High-normal blood pressure and microalbuminuria. Am J Kidney Dis 2003; 41:588.</a></li><li><a class="nounderline abstract_t">Sibley SD, Hokanson JE, Steffes MW, et al. Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes. Diabetes Care 1999; 22:1165.</a></li><li><a class="nounderline abstract_t">Freedman BI, Langefeld CD, Lohman KK, et al. Relationship between albuminuria and cardiovascular disease in Type 2 diabetes. J Am Soc Nephrol 2005; 16:2156.</a></li><li><a class="nounderline abstract_t">Mann JF, Gerstein HC, Yi QL, et al. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol 2003; 14:641.</a></li><li><a class="nounderline abstract_t">Heerspink HJL, Greene T, Tighiouart H, et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol 2019; 7:128.</a></li><li><a class="nounderline abstract_t">Hoerger TJ, Wittenborn JS, Segel JE, et al. A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening. Am J Kidney Dis 2010; 55:463.</a></li><li><a class="nounderline abstract_t">Xu R, Sun S, Huo Y, et al. Effects of ACEIs Versus ARBs on Proteinuria or Albuminuria in Primary Hypertension: A Meta-Analysis of Randomized Trials. Medicine (Baltimore) 2015; 94:e1560.</a></li><li><a class="nounderline abstract_t">Asselbergs FW, Diercks GF, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110:2809.</a></li><li><a class="nounderline abstract_t">Ibsen H, Wachtell K, Olsen MH, et al. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 2004; 22:1805.</a></li><li><a class="nounderline abstract_t">Bakris GL, Ruilope L, Locatelli F, et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int 2007; 72:879.</a></li><li><a class="nounderline abstract_t">Tuttle KR. Albuminuria reduction: the holy grail for kidney protection. Kidney Int 2007; 72:785.</a></li></ol></div><div id="topicVersionRevision">Topic 1545 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25018975" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Chapter 1: Definition and classification of CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23732715" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15983218" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The early natural history of nephropathy in Type 1 Diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19571282" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Renal and retinal effects of enalapril and losartan in type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20413961" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31540958" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Progression of Diabetic Kidney Disease in the Absence of Albuminuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31221677" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Progressive Decline in Estimated Glomerular Filtration Rate in Patients With Diabetes After Moderate Loss in Kidney Function-Even Without Albuminuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34964873" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : 11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7497874" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7821182" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Consensus development conference on the diagnosis and management of nephropathy in patients with diabetes mellitus. American Diabetes Association and the National Kidney Foundation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21617152" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21617108" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1468288" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Screening for microalbuminuria. A comparison of single sample methods of collection and techniques of albumin analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17276798" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3622198" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Single-void urine samples can be used to estimate quantitative microalbuminuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9096972" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4039920" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Urine albumin to creatinine ratio-response to exercise in diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6656849" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Use of single voided urine samples to estimate quantitative proteinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19092125" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : First morning voids are more reliable than spot urine samples to assess microalbuminuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11912263" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14520612" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32205071" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Albuminuria and Risk of Cardiovascular Events and Mortality in a General Population of Patients with Type 2 Diabetes Without Cardiovascular Disease: A Danish Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31734692" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Association of Longitudinal Trajectory of Albuminuria in Young Adulthood With Myocardial Structure and Function in Later Life: Coronary Artery Risk Development in Young Adults (CARDIA) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11466120" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14644892" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12356629" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11425768" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15210602" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15738353" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Low-grade albuminuria and the risks of hypertension and blood pressure progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12392828" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Microalbuminuria modifies the mortality risk associated with electrocardiographic ST-T segment changes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1587400" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prospective study of microalbuminuria as predictor of mortality in NIDDM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1353802" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8243850" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : UK Prospective Diabetes Study (UKPDS). X. Urinary albumin excretion over 3 years in diet-treated type 2, (non-insulin-dependent) diabetic patients, and association with hypertension, hyperglycaemia and hypertriglyceridaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2878175" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10789601" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10585306" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10585307" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Atherosclerosis profile and microalbuminuria in essential hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11875307" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12039992" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Association of the insulin resistance syndrome and microalbuminuria among nondiabetic native Americans. The Inter-Tribal Heart Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12191965" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11856780" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12955674" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Trøndelag Health Study (HUNT), Norway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7828312" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Hyperinsulinemic microalbuminuria. A new risk indicator for coronary heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15655123" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17563019" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16087792" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15811980" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15928029" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : New definition of microalbuminuria in hypertensive subjects: association with incident coronary heart disease and death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17162143" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Reevaluation by high-performance liquid chromatography: clinical significance of microalbuminuria in individuals at high risk of cardiovascular disease in the Heart Outcomes Prevention Evaluation (HOPE) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11294805" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7912295" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Microalbuminuria and endothelial dysfunction in essential hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16373905" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Impaired coronary endothelium-dependent vasodilation is associated with microalbuminuria in patients with type 2 diabetes and angiographically normal coronary arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15211434" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The relationship of cardiovascular risk factors to microalbuminuria in older adults with or without diabetes mellitus or hypertension: the cardiovascular health study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12612982" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : High-normal blood pressure and microalbuminuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10388983" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15872076" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Relationship between albuminuria and cardiovascular disease in Type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12595499" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30635226" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20116910" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26426627" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effects of ACEIs Versus ARBs on Proteinuria or Albuminuria in Primary Hypertension: A Meta-Analysis of Randomized Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15492322" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15311110" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17667984" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17882241" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Albuminuria reduction: the holy grail for kidney protection.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
